Tirzepatide (Mounjaro) : A New Era in Diabetes and Obesity Treatment

Globally, metabolic diseases—particularly Type 2 diabetes and obesity—have become some of the greatest challenges for modern medicine. Following the success of Semaglutide (Ozempic/Wegovy), the medical world is now being introduced to an even more powerful player: Tirzepatide. Known commercially as Mounjaro and Zepbound, this molecule is not just a medication; it is considered a technology that fundamentally alters how metabolism functions.

In this comprehensive guide, we will detail what Tirzepatide is, how it works, its clinical successes, and the most frequently asked questions regarding its licensing and reimbursement status in Turkey.

What is Tirzepatide? The "Dual Agonist" Revolution

Tirzepatide, developed by Eli Lilly, is the first medication classified as a "dual agonist." But what does this technical term actually mean?

While traditional treatments usually target a single hormone pathway, Tirzepatide simultaneously mimics two primary incretin hormones in the body:

1. GLP-1 (Glucagon-Like Peptide-1)

It stimulates insulin production, slows gastric emptying, and sends signals to the satiety center in the brain to suppress appetite.

2. GIP (Glucose-Dependent Insulinotropic Polypeptide)

It regulates adipose (fat) tissue function, influences energy expenditure, and synergistically enhances the effects of GLP-1. GIP is the most critical component distinguishing this drug from its predecessors because it has a direct regulatory role in fat metabolism.

This dual-action approach places Tirzepatide into a special category called "twincretin." This mechanism does not just regulate blood sugar; it also optimizes the body's fat-burning capacity, leading to dramatic results.

Clinical Success: SURPASS and SURMOUNT Trials

The reason Tirzepatide has made such a massive impact is the evidence from large-scale clinical trials showing unprecedented levels of weight loss and blood sugar control.

SURPASS Series: Type 2 Diabetes Control

These studies proved that Tirzepatide could reduce HbA1c (three-month average sugar) levels by up to 2.5% in patients with Type 2 diabetes. More importantly, when compared to placebos or existing diabetes medications, this drug demonstrated superior performance in maintaining blood sugar within target ranges.

SURMOUNT Series: The Fight Against Obesity

The obesity-focused SURMOUNT-1 trial showed that at the highest dose (15 mg), patients lost an average of 20.9% of their body weight over 72 weeks. This rate is considered a milestone in medical history as the first pharmacological treatment to approach the results of bariatric surgery.

FDA Approval and Global Brand Names

During its development, Tirzepatide received FDA (U.S. Food and Drug Administration) approval under two different commercial names for two distinct purposes:

• Mounjaro (May 2022): Approved for the treatment of Type 2 diabetes. It is generally prescribed for blood sugar management in diabetic patients.

• Zepbound (November 2023): Approved for chronic weight management (obesity treatment). It was developed for patients who do not have diabetes but struggle with obesity or excessive weight.

The European Medicines Agency (EMA) has granted similar approvals, opening the door for its use in the European market. However, global demand is so high that the manufacturer occasionally faces supply issues, leading to stock shortages even in many developed countries.

Is Mounjaro Available in Turkey? Current License Status

The most critical question for patients, their families, and physicians in Turkey is: Is Mounjaro sold in Turkey?

According to current data, Tirzepatide (Mounjaro or Zepbound) is not yet a licensed medication in Turkey.

How Does the Approval Process Work in Turkey?

For a drug to be officially available in Turkish pharmacies, it must be approved by the Turkish Medicines and Medical Devices Agency (TİTCK). The licensing process involves submitting an application, inspecting the drug's safety according to local regulations, and subsequently determining a price based on the Euro exchange rate. The completion of this process for Tirzepatide is currently awaited.

Tirzepatide Reimbursement (SGK) Status and Drug Access

The economic dimension of a medication is the most important factor determining patient access.

• SGK Coverage: For a drug to be covered by the Social Security Institution (SGK), it must first be licensed in Turkey and then included in the "Reimbursement List." Since Tirzepatide is not currently licensed in Turkey, it is not covered by SGK.

• Pricing: Because the drug is not officially available, an "Official Pharmacy Sales Price" in Turkish Lira has not been established.

• Procurement via Personal Prescription: In rare cases, life-saving medications can be brought from abroad through the Turkish Pharmacists’ Association (TEB) with TİTCK approval. However, for weight-loss medications, the procedures for this route are extremely strict.

Differences Between Tirzepatide and Semaglutide (Ozempic)

One of the most frequent questions from the public is how Tirzepatide competes with the other popular drug on the market, Semaglutide (Ozempic/Wegovy).

• Target Receptors and Mechanism of Action: Semaglutide focuses only on the GLP-1 hormone receptor. Tirzepatide, as a "dual agonist," acts on both GLP-1 and GIP receptors simultaneously. This dual action allows Tirzepatide to exert broader control over metabolic processes.

• Weight Loss Potential: Clinical trials show Tirzepatide is a step ahead in terms of weight loss. While patients using Semaglutide observe an average weight loss of 12% to 15%, those using Tirzepatide can reach 20% or higher.

• Ease of Use: Both medications are similar in terms of convenience. They are administered once a week as ready-to-use injections in pen form.

Who Should Not Use Tirzepatide?

This medication is not a lifestyle product or a cosmetic weight-loss tool; it is a serious medical treatment. Tirzepatide is not recommended in the following cases:

• History of Thyroid Cancer: Individuals with a personal or family history of Medullary Thyroid Carcinoma (MTC).

• Pancreatitis: Those who have experienced severe inflammation of the pancreas in the past.

• Type 1 Diabetes: This medication is only for Type 2 diabetes and obesity; it is not suitable for Type 1 diabetes where the body produces no insulin.

• Pregnancy and Breastfeeding: It is not recommended during these periods as its effects on infants are not yet fully understood.

Side Effects of Tirzepatide and Their Management

The most common complaints for those starting treatment are gastrointestinal and usually subside as the body adjusts to the medication:

• Nausea and Vomiting: Usually occurs during dose escalation periods.

• Delayed Gastric Emptying: While this is a desired effect for satiety, it can sometimes lead to excessive bloating.

• Diarrhea or Constipation: Consuming fibrous foods and plenty of water helps manage this process.

• Risk of Muscle Loss: Rapid weight loss can lead to muscle loss (sarcopenia). Therefore, high-protein nutrition and resistance exercises are vital during the treatment process.

Future Outlook: The Tomorrow of Obesity Treatment

Tirzepatide is just the tip of the iceberg. "Triple agonists" (such as Retatrutide) that target three different hormones (GLP-1, GIP, and Glucagon) are currently in clinical phases. However, the gold standard today remains Tirzepatide. Research continues regarding its positive effects not only on weight loss but also on sleep apnea, heart failure, and chronic kidney disease.

Conclusion

Tirzepatide (Mounjaro) is a revolutionary step in the treatment of diabetes and obesity. However, the official approval process in Turkey is still ongoing. Attempting to obtain these drugs through illegal means or unverified websites means risking your health with counterfeit products of unknown content.

Remember: The best treatment is one that is specifically planned for you and monitored by a specialist endocrinologist.

Bibliography

FDA (U.S. Food and Drug Administration): "FDA Approves Novel Dual Effector Drug for Type 2 Diabetes" (May 2022).

FDA (U.S. Food and Drug Administration): "FDA Approves New Drug Treatment for Chronic Weight Management" (Zepbound Approval - November 2023).

Eli Lilly and Company: "SURPASS and SURMOUNT Clinical Trial Results for Tirzepatide".